A randomized, open label study of the effect of Peginterferon alfa-2a (40KD) (PEGASYS) plus entecavir (Baraclude) combination therapy on quantitative changes in HBeAg in treatment-naive patients with HBeAg positive chronic hepatitis B.

Trial Profile

A randomized, open label study of the effect of Peginterferon alfa-2a (40KD) (PEGASYS) plus entecavir (Baraclude) combination therapy on quantitative changes in HBeAg in treatment-naive patients with HBeAg positive chronic hepatitis B.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 09 Jun 2016 Planned no. of patients is given as 219 in NCT, however I have retained 218 as per the results published in the Clinical Infectious Diseases (3146603)
    • 16 Apr 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 25 Mar 2010 Planned number of patients changed from 228 to 210 as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top